News coverage about MISONIX (NASDAQ:MSON) has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MISONIX earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 47.5122878902006 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
MISONIX (NASDAQ MSON) traded down 1.19% on Tuesday, hitting $8.30. The stock had a trading volume of 162 shares. MISONIX has a one year low of $4.85 and a one year high of $12.00. The company’s 50-day moving average is $8.84 and its 200-day moving average is $10.26. The stock’s market cap is $74.89 million.
Misonix, Inc designs, manufactures, develops and markets minimally invasive therapeutic ultrasonic medical devices. The Company’s products include BoneScalpel surgical system (BoneScalpel), SonaStar Surgical Aspirator (SonaStar), and SonicOne Wound Cleansing and Debridement System (SonicOne). These devices primarily serve the neurosurgery, orthopedic surgery, plastic surgery, wounds, burn and maxillo-facial clinical specialties.
Receive News & Ratings for MISONIX Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MISONIX Inc. and related companies with our FREE daily email newsletter.